Arno Ylitalo
Publications
- CLEVER-1 targeting antibody, bexmarilimab, supports HLA-DR expression and alters ex vivo responsiveness to azacitidine and venetoclax in myeloid malignancies (2025)
- Scientific Reports
(A1 Refereed original research article in a scientific journal)